76.05USD+0.65%Mkt Cap: 12.58B USDP/E: —Last update: 2026-05-26
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemi…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap12.58B USD
Enterprise Value13.16B USD
Revenue (TTM)1.06B USD
Gross Profit927.80M USD
Net Income (TTM)-381.39M USD
Revenue/Share6.550 USD
Last Price76.05 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4622221004
Valuation
P/E (Trailing)—
P/E (Forward)-121.85
PEG27.33
EV/EBITDA-38.85
EV/Revenue12.43
P/S11.83
P/B25.58
EPS (TTM)-2.01
EPS (Forward)-0.62
52W Range
32.0080% of range86.74
52W High86.74 USD
52W Low32.00 USD
Profitability
Gross Margin98.31%
Oper. Margin-47.72%
EBITDA Margin-32.00%
Profit Margin-40.41%
ROE-77.98%
ROA-10.82%
Growth
Revenue Growth87.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-268.58M USD
CapEx (TTM)57.08M USD
FCF Margin-76.34%
FCF Yield-6.42%
Net Debt632.58M USD
Net Debt/EBITDA-1.87
Balance Sheet
Debt/Equity4.22
Current Ratio4.10
Quick Ratio2.86
Book Value/Sh2.962 USD
Cash/Share11.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)100.92 USD
Target Range47.00 USD – 130.00 USD
# Analysts25
Ownership
Shares Out.165.26M
Float163.98M
Insiders0.61%
Institutions107.23%
Short Interest
Short Ratio9.1d
Short % Float13.07%
Short % Out.9.85%
Shares Short16.28M
Short (prev mo.)14.33M
Technical
SMA 5074.19 (+2.5%)
SMA 20072.01 (+5.6%)
Beta0.38
S&P 52W Chg28.31%
Avg Vol (30d)1.78M
Avg Vol (10d)1.79M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—